NEW Tobacco Company Publishing Policy
Tobacco Regulatory Science initially (2015) established a policy of not considering tobacco industry research for publication, however, also established a process of annually evaluating that decision. Effective immediately Tobacco Regulatory Science has elected to allow such papers to be considered for publication based on the premise that fair review could be accomplished and a recognition that quality research should be disseminated. Consequently, if you plan on submitting a manuscript and are directly or indirectly funded by the tobacco industry please review here.
NEW Transparency Policy
- Data Access: All authors must agree to make all relevant data and analysis codes available for external review via formal request. If that is not possible, an explanation on why that is not possible must be provided (eg, commercial confidentiality), and will be considered by the Editor-in-Chief when determining whether or not to consider an article for review. It is highly recommended that authors include their data in a repository designed for protection of scientific data in order to assure long term access to those data, study protocols, analytic coding, etc.
- Data Transparency: All authors must confirm that the research design and analysis approach employed in the research met appropriate standards indicated by the Equator Network (https://www.equator-network.org/). Articles that have deviated from those standards can be considered on a case-by-case basis by providing an explanation of that deviation, including how that deviation will be explained in the article.
- Registration of Clinical Trials: All articles that are based on clinical trial data must have been posted in a study registry prior to study implementation, including the analysis plan. Authors must provide the registration organization (eg, ClinicalTrials.gov) and registration number for that trial when submitting the article and will be reviewed by the Editor-in-Chief when determining whether or not to include the article for review. That information will not be provided to reviewers in order to maintain blinded review, but will be included in any articles accepted for publication. Exceptions will be considered on a case-by-case basis by the Editor-in-Chief, and will require a clear rationale that will be stated in the article if it is accepted for publication.
- Article Pre-Review: Authors must indicate whether permission was required by any individual, committee or organizational practice or policy prior to publication, and provide a description of that review and approval process. For example, if there is an organizational requirement that an article be reviewed internally prior to submission, that process must be described, including factors that are considered in that review process.
Tobacco Regulatory Science will consider inclusion of brief commentaries that are relevant to the regulatory process. These commentaries should generally be 1000-1500 words, and do not require an abstract or the sections required in regular manuscripts. However, all grammar and other formatting requirements are identical to those for full manuscripts (including reference formatting), so authors submitting a Commentary should consult those guidelines (see below). Commentary submissions will typically be reviewed by the Editor-in-Chief, and sometimes an outside reviewer, who will make the decision on inclusion or exclusion of submitted Commentaries. Authors are strongly encouraged contact the Editor-in-Chief before submitting a Commentary, and reference to that communication should accompany the submission.
Commentaries must conform to the American Medical Association Manual of Style (10th edition). Title should be concise but informative (do not exceed 75 characters excluding spaces). Only the first letter of each word in the title should be capitalized – all other letters should be formatted in lower case. The manuscript is in Microsoft Word Windows or Mac, double-spaced, pages numbered, and in a 12-point Times New Roman font.
Commentaries provide an in-depth discussion regarding a topic of great relevance to tobacco regulation, and though it represents the thoughts and views of the author(s), it should be a scholarly document that includes appropriate references as needed. The format should be as follows: Title, Authors, Institutions, Commentary Text that includes relevance to tobacco regulation, Conflict of Interest Disclosure Statement, Acknowledgments, References.
Conflict of Interest Disclosure Statement
Articles published in Tobacco Regulatory Science must be accompanied by a conflict of interest disclosure statement, or a statement that authors have no conflicts of interest to declare (All authors of this article declare they have no conflicts of interest). To execute this policy, all authors must privately disclose to the editors of Tobacco Regulatory Science at the time of their submission ANY and ALL potential conflicts of interest. These include financial and non-financial interests and relationships (see below for definitions), direct employment with a private sector entity (whether full-time, part-time, or on a consultancy basis), and service on private sector and non-profit boards and advisory panels, whether paid or unpaid. Authors also should disclose to editors any conflict of interest that may have influenced either the conduct or the presentation of research, including but not limited to close relationships with those who might be helped or hurt by the publication, academic interests and rivalries, and any personal, religious or political convictions relevant to the topic at hand. In the paper, authors should include a draft statement that discloses all relevant conflicts of interest and affiliations. Relevance for financial conflicts of interest with private firms is defined as a relationship of any value with a firm with a stake in the subject of the manuscript, or its competitors. Relevance for patents is defined as any invention or pending invention connected in any way to one of the authors. Because relevance is often “in the eye of the beholder,” err on the side of full disclosure in drafting the disclosure statement. Editors will check your draft against the private financial disclosure statement, and initiate discussions toward possible adjustments, if necessary.
What to report: Any financial relationship from the past 3 years (dating from the month of submission) of any size should be disclosed. These potential conflicts of interest include:
- Direct employment, either full or part-time;
- Grants and research funding (but not grants to your institution or others within your institution on which you did not work); this includes grants from trade associations and non-profits substantially (50% or more) funded by private-sector firms;
- Travel grants, speaking fees, writing fees, and other honoraria;
- Paid expert testimony for one side in an adversarial proceeding (this does not include testimony as a factual witness in a civil or criminal case);
- Patents granted, pending and applications, whether or not generating royalties;
- Stock ownership, investment in related “sector” funds, or stock options, including those of immediate family members but excluding diversified mutual funds and investment trusts; and
- Membership on private sector scientific or other advisory boards, whether paid or unpaid.
In addition, any current negotiations regarding future employment or current job offers, either full-time or part-time, must be disclosed.
In disclosing these financial arrangements to editors, authors can include dollar amounts even though they will not be printed in the journal. Editors may choose to exclude this information from publication, but in no case should an editor or author consider an arrangement irrelevant based on its size alone.
Non-Financial Conflicts of Interest: Authors may have strongly-held views about the article being submitted for publication. Authors should consider disclosing and editors may choose to print any affiliations or expressions of these views that may be relevant. These may be personal, political, or intellectual and may include any expression of strongly held views relevant to the subject of the submission. Such disclosures may be original, or they make reference to opinions previously expressed in books or monographs, op-eds or public comments, or to sworn testimony before or lobbying of legislators or legislative bodies. Non-financial conflicts of interest that should be disclosed also include membership or affiliation with non-governmental organizations that have an interest in the submission.
Enforcement: Conflict of interest disclosure relies on the honor system. Editors do not have the time or other resources to be financial auditors or ideological arbiters. Successful disclosure policies depend on the good will and integrity of authors. In all cases of failure to disclose a relevant conflict of interest of which the editors become aware, they will publish an editor’s note that becomes part of the permanent record of that article. In those rare cases where editors uncover a willful desire to conceal financial conflicts of interest, the editors will disallow publication by the author(s) in Tobacco Regulatory Science for a period of up to 3 years.
List the sources of support in the form of (1) person(s), grant(s), equipment, or drugs; and (2) note disclaimers, if any, including notices of the manuscript’s prior appearance as a preliminary report, abstract or conference proceedings.
Redact Identifying Information
Redact author or identifying information in text, Acknowledgements or References that identifies author(s) information for reviewing purposes. The redaction should be obscured with a solid black cover. Should the manuscript be accepted, the redaction will be removed.
If using a Reference Management Software similar to EndNote, Mendeley, Zetero, etc. PLEASE REMOVE. Replace with the Numbering format function in Word. The Numbering format function is next to the Bullet format function in the Tool Bar.
References should be numbered consecutively in the order in which they are mentioned in the text using the Numbering format function. No reference should be given more than one number. Identify references in text by superscript Arabic numerals. Avoid using abstracts as references unless it is available in the public domain. References to papers accepted but not yet published should be designated as “in press”; authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should not be cited. Avoid citing a personal communication unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. Authors should obtain written permission and confirmation of accuracy from the source.
Use the style of the examples below. Prepare all the references in AMA style, with the Library of Medicine (NLM) abbreviations for all journals that have them. DO NOT GUESS AT ABBREVIATIONS; USE ONLY THE LEGITIMATE ABBREVIATIONS. If no abbreviation appears in NLM then use the full title of the referenced journal. For assistance with abbreviations go to https://www.ncbi.nlm.nih.gov/nlmcatalog/journals and type in the title of the journal whose abbreviation is being sought. Make sure that the abbreviated journal titles are italicized and that a periods appears at the end of each journal.
Note: All citations listed must be accessible by the reader or it will NOT be allowed.
For secondary sources, direct quotations, and citations from books or reports, give specific page numbers. Remember; cite personal communications in text only, giving the source and date. If communication is an email: provide sender’s address. References should be listed in the following manner:
Journal Publications of up to 4 Authors (list all 4)
Mumford EA, Pearson JL, Villanti AC, Evans WD. Nicotine and e-cigarette beliefs and policy support among US smokers and nonsmokers. Tob Regul Sci. 2017;3(3):293-304.
Publications of more than 4 Authors (list only 3 followed by et al.)
Russo AR, Solis AC, Villanti AC, et al. Mentoring success in tobacco regulation science: a qualitative study. Tob Regul Sci. 2017;3(3):280-292.
US Food and Drug Administration. Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol versus Nonmenthol Cigarettes. Silver Spring, MD: Center for Tobacco Products, Food and Drug Administration; 2013.
Quoted Chapter in Books
Eriksen M and Whitney C. Risk Factors: Tobacco. In McQueen DV, Global Handbook on Noncommunicable Diseases and Health Promotion. New York: Springer. 2013, pp 115-136.
Bruce Ballantine. EPC WORKING PAPER N° 17: Enhancing the role of science in the decision-making of the European Union. European Policy Centre; 2005 (March):1-49.
Example of Online Journal Article with a DOI
Katz SJ, Weijia S, Erkkinen M, et al. High school youth and e-cigarettes: the influence of modified risk statements and flavors on e-cigarette packaging. Am J Health Behav. 2020:44(2):130-145. doi: org/10.5993/AJHB.44.2.2
Example of Online Journal Article with URL
Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics. 1986;77(4):471-476. https://pubmed.ncbi.nlm.nih.gov/3960615/. Published November 1, 2013. Accessed November 12, 2019.
Figures & Tables
Generally, tables and figures are not included in a Commentary. If the author wishes to include one, please contact the Editor-in-Chief to discuss it.
It is the responsibility of the author or authors to obtain the necessary permission to use any quoted material in excess of 25 lines that is incorporated in the manuscript. Permission must be obtained, and credit given, for quotations, tables, and illustrations borrowed from copyrighted material. Letters granting permission should accompany the manuscript when submitted.
Abbreviations and Nomenclature
Abbreviations and nomenclature should conform to the American Medical Association Manual of Style (10th edition). Abbreviations should be kept to a minimum in the text and should be defined at first usage. Periods are not used after abbreviations (eg, mm, mL). Generic names are preferred for drugs.
Once the Commentary is submitted directly to the Editor-in-Chief (EiC), the EiC will begin the internal review process, and if needed will obtain input from outside experts. If the Commentary is acceptable, the EiC will inform the lead author and begin the editing process. The EiC will then send the Commentary to the typesetter, who will do additional editing to format the paper for publication. The Commentary will appear on the TRS website at the same time as the peer-reviewed papers, and will be available in full to any reader.
Final disposition of the manuscript rests with the Editor-in-Chief.
Plagiarism Prevention Process
Prior to submission, all manuscripts are expected to have been checked for unattributed text via one of several automated software programs (eg, Grammarly, Plagiarisma, PaperRater, iThenticate, etc).
If additional questions arise, feel to contact the journal offices.
Revised June 29, 2020